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and pathological complete response rates.1 It is definitely possible that chemotherapy related
complications in some patients have the potential to cause harm by introducing prolonged delays
in cystectomy in individuals who may not harbor distant metastases.
Due to the fact that many patients in our cohort received chemotherapy from their local
oncologists, we are unable to fully characterize the specific reasons for patients receiving less
than full neoadjuvant treatment intensity. We are not suggesting that neoadjuvant chemo-
therapy harbors no risks to the patient. However, we were unable to find a significant associ-
ation between time to cystectomy and overall survival in our cohort, of whom all received
neoadjuvant chemotherapy. This finding suggests that the level of risk related to timing
of surgery may be different in patients with bladder cancer receiving systemic chemotherapy
compared to those who remain untreated from the date of transurethral resection of bladder
tumor until definitive cystectomy. Our report presents initial data on this issue, and certainly
additional data sets need to be analyzed before any definitive statements can be made.
We merely propose that our data do not support the notion that neoadjuvant chemotherapy
associated delays in cystectomy leading to a missed potential for curative intervention are
common.
In our cohort 124 patients had clinical T2,N0 disease at initiation of neoadjuvant chemo-
therapy. The therapy received in this group was consistent with the data for the overall
cohort, with a median of 3 cycles of neoadjuvant chemotherapy, a median time to cystectomy
of 195 days and a pathological complete response rate of 24% (30 patients). Median overall
survival for this group was 22.4 months. However, nearly half of the patients in this group
(58, 47%) underwent cystectomy in 2012 or later. Hence, followup for this group is immature.
We will continue to follow this cohort closely and report any new findings that come to light
with longer followup.1. Gandhi NM, Baras A, Munari E et al: Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: predicting
response and assessing outcomes. Urol Oncol 2015; 33: 204.e1.Re: Critical Analysis of Early Recurrence after Laparoscopic
Radical Cystectomy in a Large Cohort by the ESUTS. Albisinni, L. Fossion, M. Oderda, O. M. Aboumarzouk, F. Aoun, T. Tokas, V. Varca,
R. Sanchez-Salas, X. Cathelineau, P. Chlosta, F. Gaboardi, U. Nagele, T. Piechaud,
J. Rassweiler, P. Rimington, L. Salomon and R. van Velthoven
J Urol 2016; 195: 1710e1717.To the Editor: The authors critically analyze a large cohort by the European Association of
Urology Section of Uro-Technology and assess early recurrences after laparoscopic radical
cystectomy and evaluation of risk factors, including the impact of pneumoperitoneum. They
focus their analysis on patients with favorable pathology (pT2 N0 R0 disease), finding that 27 of
311 patients (8.7%) experienced recurrences during the following 24 months. Surgical negligence
was observed in only 1 patient, which was associated with the endo bag rupturing during
transvaginal extraction with subsequent vulvar and peritoneal tumor metastasis after 4 months.
Among the 27 patients with recurrence a shorter recurrence-free survival was significantly
predictive of cancer specific death (HR 0.86, 95% CI 0.78e0.94, p ¼ 0.001) as well as carcinoma
in situ on pathological examination (HR 3.68, 95% CI 1.07e12.7, p ¼ 0.039). While analyzing
causes of early recurrence, the authors suggest that the continuous insufflation-desufflation and
leakage of gas around the portsdwith consequent aspiration of tumor cells via a chimney
effectdmay promote tumor seeding (TS).1
The hypothesis correlating a cause and effect relationship of their findings with CO2 pneu-
moperitoneum conditions is coherently founded and extensively studied by implementation
of animal models, in vitro experiments, case reports and a prospective study.2,3 A model of
1320 LETTERS TO THE EDITOR/ERRATAdesufflation during laparoscopic surgery was designed by means of in vitro cell culture tools.
The impact of desufflation on survival and invasion capacities of cancer cells was tested
compared to continuous CO2 insufflation by means of an in vitro pneumoperitoneum gas box
model.4 Survival and invasion capacities of cancer cells were superior in the desufflation
model and were associated with oxidative stress. In that study desufflation during CO2
pneumperitoneum was highlighted as the triggering factor of postoperative cancer cell survival
and invasion.
However, the impact of CO2 pneumoperitoneum desufflation cannot be considered the only
triggering factor associated with port site metastasis (PSM) and TS. Indeed, in an Italian survey
on laparoscopic cystectomy an interesting aspect was the absence of tumor seeding in 83 cases
despite the longer operative time compared to open surgery (520 vs 330 minutes).5 This finding
suggests that respect of surgical oncologic principles is important to prevent TS.
Another important factor associated with TS and PSM is the origin of the tumor and its
malignant and metastatic potential. Transitional cell carcinoma is one of the most malignant
urinary tract tumors with a high grade of dissemination. Most of the published data on TS and
PSM in the urological literature are related to transitional cell carcinoma.5 Albisinni et al
suggest that tumor stage is an important prognostic factor for TS but we believe that tumor
grade is another important predictor of worse prognosis. Tumor grade usually follows tumor
stage, and patients with high grade carcinoma have higher stage disease.6 In a recent survey
Micali et al showed that in all patients with TS the histological features demonstrated a high
grade status.7
PSM is suggested as a rare complication of robotic and laparoscopic minimally invasive
surgery.8,9 We believe that superior laparoscopic surgical skills and broad oncologic expertise
should be well consolidated to perform challenging procedures such as cystectomy. In this era of
worldwide expanded laparoscopic technologies and use of laparoscopic approaches in patients
with advanced cancer TS and PSM should be considered when planning such treatment, and
desufflation should be avoided during laparoscopic procedures.
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LETTERS TO THE EDITOR/ERRATA 1321Reply by Authors: We agree with the points highlighted by Mynbaev et al. We wish to
emphasize that most of the recurrences observed were due to hematogeneous spread, thus
advancing the hypothesis that the cancerous cells spread through the venous system rather
than in the peritoneal cavity as a consequence of bladder pedicle squeezing in the Batson plexus.
We want to stress the need for further studies exploring the effect of pneumoperitoneum on
urothelial cancer dissemination, challenging the adequacy of minimally invasive surgery in
the management of such a lethal disease.Re: Consensus Guidelines for Reporting Prostate Cancer
Gleason GradeA. Zietman, E. Klein, M. J. Droller, P. Dasgupta, J. Catto and J. A. Smith, Jr.
J Urol 2016; 195: 1723.To the Editors: It was with some surprise that we read the Commentary by the editors of the
International Journal of Radiation Oncology, Biology and Physics; Urology; Urologic
Oncology; BJU International; European Urology; and The Journal of Urology regarding the
recently defined grading system for prostate cancer.1e6 For clarification the Commentary
published in The Journal of Urology is titled “Stage Grouping,” which would appear to be an
error.
In the Commentary it was noted that the modifications to the Gleason grading systems have
been endorsed by the International Society of Urological Pathology (ISUP). In reality this is not
the case. The consensus conference held in Chicago on November 1, 2014 was convened under
the auspices of the ISUP but the attendees were selected and, unlike other ISUP consensus
conferences, attendance was not open to the full membership of the society. The modifications to
the Gleason grading system published in the American Journal of Surgical Pathology have
never been formally endorsed by either the Council or the membership of the ISUP. What has
been discussed is the terminology that has been applied to the grading system and the ISUP
Council has unanimously endorsed the name ISUP Grade as the meeting was coordinated under
the auspices of the ISUP.
The Commentary refers to the new system as Grade Groups rather than ISUP Grade.
This terminology appears in the latest edition of the World Health Organization (WHO)
classification.7 However, it should be noted that this was not adopted by consensus but,
rather, was a stop-gap measure proposed by the chair of the WHO Prostate Cancer Com-
mittee. While the final sentence of the definitive grading paper is “The new grading system
and the terminology Grade Groups 1-5,” has also been accepted for volume 8 of the 4th
edition of the WHO series on histological and genetic typing of human tumors,7 the phrase
and the terminology “Grade Groups 1-5” were added to the proof of the article without the
knowledge of at least some of the authors. As such, this statement is not endorsed by the
ISUP. It should be noted that the term Grade Group is entirely inappropriate as the new
grading system is a combination of Gleason scores and Gleason grades, and indeed is pri-
marily score based.
Interestingly, there has been much debate in the pathology literature concerning the termi-
nology and content of the new grading system, and it is clear that the grading system requires
modification. We have recently outlined some of these concerns regarding grading terminology
and criteria elsewhere, including a commentary in BJU International,8e11 although this appears
to have been overlooked by the authors of the Commentary. Such is our concern that we have
made recommendations regarding a re-working of the system.9e11
Over the years the ISUP has endorsed recommendations regarding issues relating to pros-
tate and renal cancer reporting.12,13 However, these have never been the subject of a directive
in the literature with respect to their implementation. We believe to do so is inappropriate and
this has the effect of stifling academic debate. No such encouragement/requirement in relation
to prostate cancer grading has appeared in the pathology literature and we believe that this is
